Phase 1/2 study of mRNA-3927 in participants with propionic acidemia

• Research type

  Research Study

• Full title

  A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia

• IRAS ID

  1003463

• Contact name

  Tarekegn Hiwot

• Contact email

  tarekegn.geberhiwot@uhb.nhs.uk

• Eudract number

  2019-003529-36

• Clinicaltrials.gov Identifier

  NCT04159103

• REC name

  North East - York Research Ethics Committee

• REC reference

  20/NE/0251

• Date of REC Opinion

  18 Dec 2020

• REC opinion

  Further Information Favourable Opinion